WO2020035782A1 - Molecular probes for analysis of metabolism of glycolysis inhibitors prodrugs and synthesis methods therefore - Google Patents

Molecular probes for analysis of metabolism of glycolysis inhibitors prodrugs and synthesis methods therefore Download PDF

Info

Publication number
WO2020035782A1
WO2020035782A1 PCT/IB2019/056853 IB2019056853W WO2020035782A1 WO 2020035782 A1 WO2020035782 A1 WO 2020035782A1 IB 2019056853 W IB2019056853 W IB 2019056853W WO 2020035782 A1 WO2020035782 A1 WO 2020035782A1
Authority
WO
WIPO (PCT)
Prior art keywords
glucal
benzyl
mmol
dryness
evaporated
Prior art date
Application number
PCT/IB2019/056853
Other languages
French (fr)
Inventor
Donald Picker
Original Assignee
Dermin Sp. Z O.O.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dermin Sp. Z O.O. filed Critical Dermin Sp. Z O.O.
Publication of WO2020035782A1 publication Critical patent/WO2020035782A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10Oxygen atoms

Definitions

  • the present invention relates to the field of glycolysis inhibitors and their produgs, especially to the metabolism of such glycolysis inhibitors in the body.
  • Glycolysis inhibitors are of high interest in clinical research and the pharmaceutical field due to their potential use as therapeutics.
  • Potential indications include anti -diabetes (e.g. acarbose and miglitol) or anti-viral (e.g. oseltamivit or zanamivir) applications.
  • R 1 to R 3 is -OCOCD 3 and the other two are either hydroxyl or OAc.
  • At least one of R 1 to R 3 is hydroxyl.
  • either R 1 or R 3 is -OCOCD3.
  • the present invention furthermore relates to a synthesis method for compounds according to the present invention, involving the steps of a) reacting a suitable precursor compound with a silylating agent to obtain a monosilyl- protected precursor compound b) optional protecting of further hydroxy groups of the compound obtained in step a) by orthogonal protective groups c) detachment of the silyl protective group
  • step b) acetylation of the deprotected group to introduce a -CO-CD 3 group e) optional deprotection of the protected hydroxy groups in step b)
  • Another advantage of the inventive synthesis method is the introduction of the (precious) deuteriated group at a late stage of the synthesis. It is especially preferred that a sterically demanding silyl group is used in step a), especially if R 1 is to contain the deuteriated group.
  • Silyl groups with t-butyl and/or aryl groups are especially preferred, most preferred is TBDMS (t-Butyldimetylsilyl). These silyl groups are known to prefer primary hydroxy groups over secondary or tertiary group, so that a high selectivity in the silylation can be reached.
  • step b) especially benzyl and/or substituted benzyl groups are preferred due to their orthogonality with silyl groups.
  • Step e) can then subsequentially occur using hydrogenation, preferably under Pd catalysis.
  • Step c) can be performed using fluorides, with TBAF (Tertbutylammonium fluoride) especialyl preferred.
  • step d) especially per-deuterated acetyl anhydride and/or deuterated acyl halides, especially deuterated acyl chloride are preferred, with per-deuterated acetyl anhydride especially preferred.
  • the hydroxy group at C-l (the glycosidylic hydroxy group) can be inserted by hydration of a double bond between C-l and C-2 (i.e. the precursor compound(s) include glucals and/or glucal derivatives).
  • the precursor compound(s) include glucals and/or glucal derivatives.
  • the precursor compound in step a) is a glucal or glucal derivative and the method includes a step f) which can be performed after step d) or e) f) hydration of the double bond between C-l and C-2
  • Step f) can be performed by first adding aqueos solution of H-Hal (with Cl and Br especially preferred), followed by neutralization, preferably by carbonate, hydrogen carbonate and/or phosphate solution, wich hydrogen carbonate solution especially preferred.
  • the present invention furthermore relates to the use of the inventive compounds for the analysis of the metabolism of glycolysis inhibitors.
  • the present invention furthermore relates to an analysis method for the metabolism of glycolysis inhibitors including the step of subjecting the inventive compounds in an assay.
  • the assay can be in vitro or in vivo.
  • Tri-O-acetyl-D-glucal (1) (10 g, 36.7 mmol) suspension in phosphate buffer (pH 6) (100 mL) and acetonitrile (10 mL) was prepared and Amanolipase (10 g) was added. The reaction mixture was stirred overnight at room temperature. The reaction mixture was then filtered through Celite, and filtrate was extracted with ethyl acetate (3 x 75 mL). Combined extracts were dried with NaiSCri. Drying agent was filtered off and solvent was evaporated to dryness. Crude product was purified by short column chromatography using hexanes/ethyl acetate gradient for elution.
  • D-Glucal (10) (7.85 g, 53.7 mmol) was dissolved in DMF (20 mL). Imidazole (6.1 g, 90 mmol) was added and obtained solution was cooled to 0°C. Tert-butyldimethylsilyl chloride (8.9 g, 59.1 mmol) was added and the reaction mixture was stirred at 0°C overnight.
  • reaction mixture was diluted with ethyl acetate (100 mL), washed with water (3 x 100 mL), and then dried over NaiSCri. Drying agent was filtered off and solvent was evaporated to dryness and product was separated using column
  • 6-O-tert-butyldimethylsilyl-D-glucal (11) (4.5 g, 17.3 mmol) was dissolved in DMF (45 mL), and obtained solution was cooled to -20°C.
  • Sodium hydride (60% suspension in mineral oil) (1.52 g, 38 mmol) was added followed by benzyl bromide (4.5 mL, 38 mmol).
  • the reaction mixture was stirred at -20°C for 30 min., then cooling bath was removed and stirring was continued when temperature was allowed to rise to ambient. After reaction was completed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Saccharide Compounds (AREA)

Abstract

The present invention relates to compounds according to structure (I) whereby one of R1 to R3 is -OCOCD3 and the other two are either hydroxyl or OAc, their synthesis and their use in for the analysis of the metabolism of glycolysis inhibitors.

Description

Figure imgf000002_0001
Molecular probes for analysis of metabolism of glycolysis inhibitors prodrugs and synthesis methods therefore
D e s c r i p t i o n
The present invention relates to the field of glycolysis inhibitors and their produgs, especially to the metabolism of such glycolysis inhibitors in the body.
Glycolysis inhibitors are of high interest in clinical research and the pharmaceutical field due to their potential use as therapeutics. Potential indications include anti -diabetes (e.g. acarbose and miglitol) or anti-viral (e.g. oseltamivit or zanamivir) applications.
The metabolism of these inhibitors in the human body, however, is inter alia vital for the usage of those inhibitors as potential drugs and therefore there is a constant need for compounds which are useful in the analysis of the metabolism of glycolysis inhibitors as well as synthesis methods for those compounds.
It is therefore an object to provide such compounds, especially compounds which are deuterated at predefinied moieties, and synthesis methods therefor. This object is met by compounds according to Claim 1 of the present invention. Accordingly, compounds according to structure (I) are provided
Figure imgf000003_0001
whereby one of R1 to R3 is -OCOCD3 and the other two are either hydroxyl or OAc.
It has been shown that these compounds are valuable in the analysis of the metabolism of glycolysis inhibitors, especially due to their defined deuteration pattern.
According to a preferred embodiment of the present invention, at least one of R1 to R3 is hydroxyl.
According to a preferred embodiment of the present invention, either R1 or R3 is -OCOCD3.
The present invention furthermore relates to a synthesis method for compounds according to the present invention, involving the steps of a) reacting a suitable precursor compound with a silylating agent to obtain a monosilyl- protected precursor compound b) optional protecting of further hydroxy groups of the compound obtained in step a) by orthogonal protective groups c) detachment of the silyl protective group
Figure imgf000004_0001
d) acetylation of the deprotected group to introduce a -CO-CD3 group e) optional deprotection of the protected hydroxy groups in step b)
It has been shown that by doing so it is possible to synthesize the inventive compounds in a straightforward fashion. Another advantage of the inventive synthesis method is the introduction of the (precious) deuteriated group at a late stage of the synthesis. It is especially preferred that a sterically demanding silyl group is used in step a), especially if R1 is to contain the deuteriated group. Silyl groups with t-butyl and/or aryl groups are especially preferred, most preferred is TBDMS (t-Butyldimetylsilyl). These silyl groups are known to prefer primary hydroxy groups over secondary or tertiary group, so that a high selectivity in the silylation can be reached.
In step b) especially benzyl and/or substituted benzyl groups are preferred due to their orthogonality with silyl groups. Step e) can then subsequentially occur using hydrogenation, preferably under Pd catalysis. Step c) can be performed using fluorides, with TBAF (Tertbutylammonium fluoride) especialyl preferred.
In step d) especially per-deuterated acetyl anhydride and/or deuterated acyl halides, especially deuterated acyl chloride are preferred, with per-deuterated acetyl anhydride especially preferred.
It goes without saying that further synthesis steps can be performed between any of the steps a) to e). For example the hydroxy group at C-l (the glycosidylic hydroxy group) can be inserted by hydration of a double bond between C-l and C-2 (i.e. the precursor compound(s)
Figure imgf000005_0001
include glucals and/or glucal derivatives). Subsequently, according to a preferred
embodiment, the precursor compound in step a) is a glucal or glucal derivative and the method includes a step f) which can be performed after step d) or e) f) hydration of the double bond between C-l and C-2
Step f) can be performed by first adding aqueos solution of H-Hal (with Cl and Br especially preferred), followed by neutralization, preferably by carbonate, hydrogen carbonate and/or phosphate solution, wich hydrogen carbonate solution especially preferred.
The present invention furthermore relates to the use of the inventive compounds for the analysis of the metabolism of glycolysis inhibitors.
The present invention furthermore relates to an analysis method for the metabolism of glycolysis inhibitors including the step of subjecting the inventive compounds in an assay.
The assay can be in vitro or in vivo.
The aforementioned components, as well as the claimed components and the components to be used in accordance with the invention in the described embodiments, are not subject to any special exceptions with respect to their size, shape, material selection and technical concept such that the selection criteria known in the pertinent field can be applied without limitations.
Additional details, characteristics and advantages of the object of the invention are disclosed in the subclaims and the following description of the examples. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are intended to provide further explanation of the present invention as claimed.
Figure imgf000006_0001
1. Synthesis of 3-0-trideuteroacetyl-2-deoxy-D-glucose (9)
Figure imgf000006_0002
1.1. Synthesis of 3,6-di-O-acetyl-D-glucal (2)
Tri-O-acetyl-D-glucal (1) (10 g, 36.7 mmol) suspension in phosphate buffer (pH 6) (100 mL) and acetonitrile (10 mL) was prepared and Amanolipase (10 g) was added. The reaction mixture was stirred overnight at room temperature. The reaction mixture was then filtered through Celite, and filtrate was extracted with ethyl acetate (3 x 75 mL). Combined extracts were dried with NaiSCri. Drying agent was filtered off and solvent was evaporated to dryness. Crude product was purified by short column chromatography using hexanes/ethyl acetate gradient for elution. Fractions contained product were pooled together and evaporated to dryness to give 7.4 g of 3,6-di-O-acetyl-D-glucal (yield 87.5%). Ή NMR spectra were in the agreement with the literature data.
1.2. Synthesis of 3,6-di-0-acetyl-3-0-tert-butyldimethylsilyl-D-glucal (3)
Obtained in previous step 3,6-di-O-acetyl-D-glucal (2) (7.4 g, 32.1 mmol) was dissolved in dichloromethane (100 mL). Imidazole (4g, 60 mmol) followed by tert-butyldimethylsilyl chloride (5.8 g, 38.5 mmol) were added and the reaction mixture was stirred at room temperature. Progress of the reaction was monitored using TLC method. After reaction was completed the reaction mixture was diluted with dichloromethane (100 mL), washed with
Figure imgf000007_0001
water (3 x 100 mL), and then dried over NaiSCri. Drying agent was filtered off and solvent was evaporated to dryness to give crude 3,6-di-0-acetyl-3-0-tert-butyldimethylsilyl-D-glucal (Yield quantitative) which without further purification was used in the next step. The structure of the product was confirmed by Ή NMR method and compared with literature.
1.3. Synthesis of 3-O-tert-butyldimethylsilyl-D-glucal (4)
Crude 3,6-di-0-acetyl-3-0-tert-butyldimethylsilyl-D-glucal (3) (~32 mmol) was dissolved in methanol (100 mL). Solution of 1N sodium methoxide in methanol (1 mL, 1 mmol) was added and the reaction mixture was stirred at room temperature until substrate was fully deacetylated (TLC). After reaction was completed acetic acid (1 mmol) was added, and the reaction mixture was stirred at room temperature for additional 10 min. then solvent was evaporated to dryness. 3-O-tert-butyldimethylsilyl-D-ghical was obtained in quantitative yield with purity that allowed to proceed to the next step without further purification. Ή NMR spectra of the product was acquired and compare with the literature.
1.4. Synthesis of 3,6-di-0-benzyl-3-0-tert-butyldimethylsilyl-D-glucal (5)
Crude 3-O-tert-butyldimethylsilyl-D-glucal (4) (~32 mmol) was dissolved in DMF (50 mL), and obtained solution was cooled to -20°C. Sodium hydride (60% suspension in mineral oil) (2.8 g, 70.4 mmol) was added followed by benzyl bromide (8.4 mL, 70.4 mmol). The reaction mixture was stirred at -20°C for 30 min., then cooling bath was removed and stirring was continued and temperature was allowed to rise to ambient. After reaction was completed (TLC analysis), the reaction mixture was diluted with hexanes (150 mL) and then water (100 mL) was added dropwise to neutralize excess of NaH. After 30 min. of vigorous stirring solution layers were separated. Organic layer was washed with water until neutral, and dried with NaiSOu Drying agent was filtered off and solvent was evaporated to dryness to give crude 3,6-di-0-benzyl-3-0-tert-butyldimethylsilyl-D-glucal (Yield quantitative) which
Figure imgf000008_0001
without further purification was used in the next step. The structure of the product was confirmed by Ή NMR method and compared with literature.
1.5. Synthesis of 3,6-di-O-benzyl-D-glucal (6)
Crude 3,6-di-0-benzyl-3-0-tert-butyldimethylsilyl-D-glucal (5) (3.8 g, 8.6 mmol) was dissolved in THF (38 mL). Tetra-butylammonium fluoride (2.25 g, 8.6 mmol) was added and the reaction mixture was stirred at room temperature. After reaction was completed (TLC) solvent was evaporated to dryness and ethyl acetate (60 mL) was added. Obtained solution was washed with water (3 x 50 mL) then dried over Na2S04. Drying agent was filtered off and solvent was evaporated to dryness to give crude 3,6-di-O-benzyl-D-glucal which without further purification was used in the next step. The structure of the product was confirmed by Ή NMR method and compared with literature.
1.6. Synthesis of 3,6-di-0-benzyl-3-0-trideuteroacetyl-D-glucal (7)
3,6-di-O-benzyl-D-glucal (6) (2.8 g, 8.6 mmol) was dissolved in dichloromethane (28 mL). Pyridine (0.7 mL) followed by per-deuterated acetyl anhydride (0.81 mL, 8.6 mmol) were added and the reaction mixture was stirred at room temperature overnight. After reaction was completed the reaction mixture was diluted with DCM (50 mL) and washed with 10% Na2C03 water solution, then with water until neutral and dried over Na2S04. Drying agent was filtered off and solvent was evaporated to dryness, and product was purified by column chromatography using hexanes/ethyl acetate gradient for elution. Fractions contained product were pooled together and evaporated to dryness to give 2.73 g of 3,6-di-0-benzyl-3-0- trideuteroacetyl-D-glucal (Yield 85.3%)
¾ NMR (CDCb, d, ppm), 7.38 - 7.22 (m, 10 H, Harom), 6.44 (dd, 1H, J = 6.0 Hz, J = 1.2 Hz), 5.43 (ddd, 1H, J = 6.2 Hz, J = 2.7 Hz, J = 1.1 Hz), 4.75 (dd, 1H, J = 6.1 Hz, J = 2.9 Hz), 4.70 (d, 1H, J = 11.5 Hz), 4.66 (d, 1H, J = 8.3 Hz), 4.59 (d, 1H, J = 8.3 Hz), 4.56 (d, 1H, J =
Figure imgf000009_0001
11.5 Hz), 4.09 (ddd, 1H, J = 8.7 Hz, J = 4.5 Hz, J = 3.1 Hz), 3.93 (dd, 1H, J = 8.7 Hz, J = 6.3 Hz), 3.83 (dd, 1H, J = 10.8 Hz, J = 4.5 Hz), 3.75 (dd, 1H, J = 10.8 Hz, J = 3.1 Hz)
1.7. Synthesis of 3,6-di-0-benzyl-3-0-trideuteroacetyl-2-deoxy-D-glucose (8)
3.6-di-0-benzyl-3-0-trideuteroacetyl -D-glucal (7) (2.73 g, 7.35 mmol) was dissolved in THF (27 mL). 48% HBr water solution (1 mL, 8.8 mmol) was added and the reaction mixture was stirred at room temp until all substrate was consumed (TLC). Reaction mixture was diluted with water (30 mL), then NaHCCb (8.8 mmol, 0.74 g) was added, and the reaction mixture was stirred additional 15 min. Ethyl acetate (50 mL) was added and layers were separated. Organic layer was washed with water (2 x 25 mL) and dried over Na2S04. Drying agent was filtered off and solvent was evaporated to dryness, and product was purified by column chromatography using hexanes/ethyl acetate gradient for elution. Fractions contained product were pooled together and evaporated to dryness to give 1.8 g of 3,6-di-0-benzyl-3-0- trideuteroacetyl-2-deoxy-D-glucose (Yield 62.9%).
1.8. Synthesis of 3-0-(trideuteroacetyl-2-deoxy-D-glucose (9)
3.6-di-0-benzyl-3-0-trideuteroacetyl-2-deoxy-D-glucose (8) (1.8 g, 4.6 mmol), was dissolved in THF (20 mL). Pd(OH)2/C (20% wet, Degussa) (290 mg) was added and the mixture was hydrogenated using Paar apparatus (p = 45 psi) for 1.5 h, then reaction mixture was filtered through Celite. Filtrate was evaporated to dryness, and product was purified by column chromatography using DCM/Methanol gradient for elution Fractions contained product were pooled together and evaporated to dryness to give 0.87g of 3-0-trideuteroacetyl-2-deoxy-D- glucose (Yield 90 %).
2. Synthesis of 6-0-trideuteroacetyl-2-deoxy-D-glucose (16)
Figure imgf000010_0001
2.1. Synthesis of 6-O-tert-butyldimethylsilyl-D-glucal (11)
D-Glucal (10) (7.85 g, 53.7 mmol) was dissolved in DMF (20 mL). Imidazole (6.1 g, 90 mmol) was added and obtained solution was cooled to 0°C. Tert-butyldimethylsilyl chloride (8.9 g, 59.1 mmol) was added and the reaction mixture was stirred at 0°C overnight.
After reaction was completed the reaction mixture was diluted with ethyl acetate (100 mL), washed with water (3 x 100 mL), and then dried over NaiSCri. Drying agent was filtered off and solvent was evaporated to dryness and product was separated using column
chromatography using hexanes/ethyl acetate gradient for elution. Fractions contained product were pooled together and evaporated to dryness to give 8.7 g of 6-O-tert-butyldimethylsilyl- D-glucal (Yield 62 %). The structure of the product was confirmed by Ή NMR method and compared with literature .
2.2. Synthesis of 3,4-di-0-benzyl-6-0-tert-butyldimethylsilyl-D-glucal (12)
6-O-tert-butyldimethylsilyl-D-glucal (11) (4.5 g, 17.3 mmol) was dissolved in DMF (45 mL), and obtained solution was cooled to -20°C. Sodium hydride (60% suspension in mineral oil) (1.52 g, 38 mmol) was added followed by benzyl bromide (4.5 mL, 38 mmol). The reaction mixture was stirred at -20°C for 30 min., then cooling bath was removed and stirring was continued when temperature was allowed to rise to ambient. After reaction was completed
Figure imgf000011_0001
(TLC), the reaction mixture was diluted with hexanes (120 mL) and water (100 mL) was added dropwise to neutralize excess of NaH. After 30 minut of vigorous stirring layers were separated. Organic layer was washed with water until neutral, and dried with Na2S04. Drying agent was filtered off and solvent was evaporated to dryness and product was separated using column chromatography using hexanes/ethyl acetate gradient for elution. Fractions contained product were pooled together and evaporated to dryness to give 5.5 g of 3,4-di-0-benzyl-6-0- tert-butyldimethylsilyl-D-glucal (Yield 72.2 %). The structure of the product was confirmed by Ή NMR method and compared with literature. The structure of the product was confirmed by Ή NMR method and compared with literature.
2.3. Synthesis of 3,4-di-O-benzyl-D-glucal (13)
3.4-di-0-benzyl-6-0-tert-butyldimethylsilyl-D-glucal (12) (5.5 g, 12.5 mmol) was dissolved in THF (55 mL). Tetra-butylammonium fluoride (3.3 g, 12.5 mmol) was added and the reaction mixture was stirred at room temperature. After reaction was completed (TLC) solvent was evaporated to dryness and ethyl acetate (100 mL) was added. Obtained solution was washed with water (3 x 50 mL) then dried over NaiSOu Drying agent was filtered off and solvent was evaporated to dryness to give crude 3,6-di-O-benzyl-D-glucal (Yield:
quantitative), which without further purification was used in the next step. The structure of the product was confirmed by Ή NMR method and is in the agreement with literature data.
2.4. Synthesis of 3,4-di-0-benzyl-6-0-trideuteroacetyl -D-glucal (14)
3.4-di-O-benzyl-D-glucal (13) (4.3 g, 13.2 mmol) was dissolved in dichloromethane (43 mL). Pyridine (2.2 mL) followed by per-deuterated acetyl anhydride (1.24 mL, 13.2 mmol) were added and the reaction mixture was stirred at room temperature overnight. After reaction was completed the reaction mixture was diluted with DCM (50 mL) and washed with 10%
Na2C03 water solution, then with water until neutral and dried over NarSOu Drying agent was filtered off and solvent was evaporated to dryness, and product was purified by column
Figure imgf000012_0001
chromatography using hexanes/ethyl acetate gradient for elution. Fractions contained product were pooled together and evaporated to dryness to give 4.4 g of 3,4-di-0-benzyl-6-0- trideuteroacetyl -D-glucal (Yield 89.8%)
¾ NMR (CDCb, d, ppm), 7.40 - 7.28 (m, 10 H, Harom), 6.40 (dd, 1H, J = 6.2 Hz, J = 1.2 Hz), 4.95 (dd, 1H, J = 6.1 Hz, J = 2.7 Hz), 4.86 (d, 1H, J = 11.3 Hz), 4.67 (d, 2H, J = 11.1 Hz), 4.59 (d, lH, J = 11.1 Hz), 4.41 (dd, 1H, J = 12.1 Hz, J = 2.9 Hz), 4.35 (dd, 1H, J = 12.1 Hz, J = 5.2 Hz), 4.23 (ddd, 1H, J = 6.0 Hz, J = 2.6 Hz, J = 1.3 Hz), 4.10 (ddd, 1H, J = 8.5 Hz, J = 5.2 Hz, J = 2.9 Hz), 3.77 (dd, 1H, J = 8.5 Hz, J = 6.1 Hz)
2.5. Synthesis of 3,4-di-0-benzyl-6-0-trideuteroacetyl-2-deoxy-D-glucose (15)
3.4-di-0-benzyl-6-0-trideuteroacetyl-D-glucal (14) (4.4 g, 11.8 mmol) was dissolved in THF (44 mL). 48% HBr water solution (1 mL, 8.8 mmol) was added and the reaction mixture was stirred at room temp until all substrate was consumed (TLC). Reaction mixture was diluted with water (50 mL), then NaHCCb (8.8 mmol, 0.74 g) was added, and the reaction mixture was stirred additional 15 min. Ethyl acetate (100 mL) was added and layers were separated. Organic layer was washed with water (2 x 50 mL) and dried over Na2S04. Drying agent was filtered off and solvent was evaporated to dryness, and product was purified by column chromatography using hexanes/ethyl acetate gradient for elution. Fractions contained product were pooled together and evaporated to dryness to give 4.1 g of 3,4-di-0-benzyl-6-0- trideuteroacetyl-2-deoxy-D-glucose (Yield 89.1 %)
2.6. Synthesis of 6-0-trideuteroacetyl-2-deoxy-D-glucose (16)
3.4-di-0-benzyl-6-0-trideuteroacetyl-2-deoxy-D-glucose (15) (4.1 g, 10.5 mmol) was dissolved in THF (50 mL). Pd(OH)2/C (20% wet, Degussa) (530 mg) was added and the mixture was hydrogenated using Paar apparatus (p = 45 psi) for 1.5 h, then reaction mixture was filtered trough Celite. Filtrate was evaporated to dryness, and product was purified by column chromatography using DCM/Methanol gradient for elution Fractions contained
Figure imgf000013_0001
product were pooled together and evaporated to dryness to give 2.1 g of 6-O-trideuteroacetyl- 2-deoxy-D-glucose (Yield 96 %)
¾ NMR (MeOD-3, d, ppm) 5.33 (d, 1H, J = 3.0 Hz), 4.91 (dd, 1H, J = 9.8 Hz, J = 2.0 Hz), 4.36 (dd, 1H, J = 12.2 Hz, J = 2.2 Hz), 4.30 (d, 2H, J = 3.5 Hz), 4.22 (dd, 1H, J = 12.1Hz, J = 5.3 Hz), 4.00 - 3.85 (m, 1H), 3.53 (ddd, 1H, J = 9.8 Hz, J = 5.3 Hz, J = 2.2 Hz), 3.37 (dd, 1H,
J = J = 9.6 Hz), 3.31 (dd, J = J = 10.2 Hz), 2.24 (ddd, J = 12.5 Hz, J = 5.0 Hz, J = 2.0 Hz),
2.10 (ddd, 1H, J = 13.4 Hz, J = 5.0 Hz, J = 1.0 Hz), 1.67 (ddd, 1H. J = 11.9 Hz, J = 9.8 Hz, J = 3.6 Hz), 1.49 (ddd, 1H, J = 12.1 Hz, J = 9.8 Hz, J = 12.1 Hz)
a:b ratio ~l : l
3. Synthesis of 6-0-acetyl-3-0-trideuteroacetyl-2-deoxy-D-glucose (23)
Figure imgf000013_0002
3.1. Synthesis of 4-0-benzyl-6-tert-butyldimethylsilyl-D-glucal (18)
4-O-Benzyl-D-glucal (17) (2.65 g, 11.2 mmol) was dissolved in dichloromethane (26 mL). Imidazole (1.26 g, 18.45 mmol) followed by tert-butyldimethylsilyl chloride (1.86 g, 12.3 mmol) were added and the reaction mixture was stirred at room temperature. Progress of the reaction was monitored using TLC method. After reaction was completed the reaction mixture was diluted with dichloromethane (100 mL), washed with water (3 x 100 mL), and then dried over NaiSCL. Drying agent was filtered off and solvent was evaporated to dryness and product was purified by column chromatography using hexanes/ethyl acetate gradient for
Figure imgf000014_0001
elution. Fractions contained product were pooled together and evaporated to dryness to give
3.3 g of 4-0-benzyl-6-tert-butyldimethylsilyl-D-glucal (Yield 87.8%). The structure of the product was confirmed by Ή NMR method and compared with literature.
3.2. Synthesis of 4-0-benzyl-6-tert-butyldimethylsilyl-3-0-trideuteroacetyl-D-glucal (19)
4-0-benzyl-6-tert-butyldimethylsilyl-D-glucal (3.3 g, 9.9 mmol) was dissolved in
dichloromethane (30 mL). Pyridine (1.4 mL) followed by per-deuterated acetyl anhydride (1.15 mL, 11.8 mmol) were added and the reaction mixture was stirred at room temperature overnight. After reaction was completed the reaction mixture was diluted with DCM (100 mL) and washed with 10% NaiCCh water solution, then with water until neutral and dried over NaiSCri. Drying agent was filtered off and solvent was evaporated to dryness, and product was purified by column chromatography using hexanes/ethyl acetate gradient for elution. Fractions contained product were pooled together and evaporated to dryness to give
3.4 g of 4-0-benzyl-6-tert-butyldimethylsilyl-3-0-trideuteroacetyl-D-glucal (Yield 86.7%)
¾ NMR (CDCb, d, ppm), 7.36 - 7.28 (m, 5 H, Harom), 6.41 (dd, 1H, J = 6.1 Hz, J = 1.3 Hz), 5.41 (ddd, 1H, J = 6.4 Hz, J = 3.0 Hz, J = 1.7 Hz), 4.73 (s, 2H), 4.71 (dd, 1H, J = 6.0 Hz, J = 2.9 Hz), 4.0 - 3.8 (m, 4H), 0.91 (s, 9H), 0.08 (s, 6H)
3.3. Synthesis of 4-0-benzyl-3-0-trideuteroacetyl-D-glucal (20)
4-0-benzyl-6-tert-butyldimethylsilyl-3-0-trideuteroacetyl-D-glucal (3.4 g, 8.6 mmol) was dissolved in THF (35 mL). Tetra-butylammonium fluoride (2.24 g, 8.6 mmol) was added and the reaction mixture was stirred at room temperature. After reaction was completed (TLC) solvent was evaporated to dryness and ethyl acetate (100 mL) was added. Obtained solution was washed with water (3 x 50 mL) then dried over Na2S04. Drying agent was filtered off and solvent was evaporated to dryness product was purified by column chromatography using hexanes/ethyl acetate gradient for elution. Fractions contained product were pooled together
Figure imgf000015_0001
and evaporated to dryness to give 1.6 g of 4-0-benzyl-3-0-trideuteroacetyl-D-glucal (Yield 66.1%)
¾ NMR (CDCb, d, ppm), 7.36 - 7.28 (m, 5 H, Harom), 6.41 (dd, 1H, J = 6.0 Hz, J = 1.4 Hz), 5.46 (ddd, 1H, J = 6.7 Hz, J = 2.5 Hz, J = 1.5 Hz), 4.76 (dd, 1H, J = 6.0 Hz, J = 2.6 Hz), 4.74 (d, lH, J = 11.6 Hz), 4.70 (d, 1H, J = 11.6 Hz), 4.0 - 3.84 (m, 4H), 1.81 (dd, 1H, J = 6.8 Hz,
H = 6.4 Hz)
3.4. Synthesis of 6-0-acetyl-4-0-benzyl-3-0-trideuteroacetyl-D-glucal (21)
4-0-benzyl-3-0-trideuteroacetyl-D-glucal (1.6 g, 5.7 mmol) was dissolved in
dichloromethane (20 mL). Pyridine (0.7 mL) followed by acetyl chloride (0.45 mL, 6.26 mmol) were added and the reaction mixture was stirred at room temperature. After reaction was completed (TLC) the reaction mixture was diluted with DCM (100 mL) and washed with 10% NaiCCb water solution, then with water until neutral and dried over NaiSCri. Drying agent was filtered off and solvent was evaporated to dryness, and product was purified by column chromatography using hexanes/ethyl acetate gradient for elution. Fractions contained product were pooled together and evaporated to dryness to give 1.76 g of 6-0-acetyl-4-0- benzyl-3-O-trideuteroacetyl-D-glucal (Yield 95.5%)
¾ NMR (CDCL, d, ppm), 7.40 - 7.28 (m, 5 H, Harom), 6.42 (dd, 1H, J = 6.1 Hz, J = 1.1 Hz), 5.45 - 5.39 (m, lH), 4.8 l (dd, 1H, J = 6.1 Hz, J = 3.1 Hz), 4.72 (d, 1H, J = 11.6 Hz), 4.64 (d, lH, J = 11.6 Hz), 4.40 (dd, 1H, J = 12.1 Hz, J = 3.2 Hz), 4.32 (dd, 1H, J = 12.1 Hz, J = 5.3 Hz), 4.16 (ddd, 1H, J = 8.1 Hz, J = 5.3 Hz, J = 3.2 Hz), 3.81 (dd, 1H, J = 8.1 Hz, J = 6.0 Hz), 2.07 (s, 3H)
3.5. Synthesis of 6-0-acetyl-4-0-benzyl-3-0-trideuteroacetyl-2-deoxy-D-glucose (22)
6-0-acetyl-4-0-benzyl-3-0-trideuteroacetyl-D-glucal (1.76 g, 5.4 mmol) was dissolved in THF (20 mL). 48% HBr water solution (0.61 mL, 5.4 mmol) was added and the reaction mixture was stirred at room temp until all substrate was consumed (TLC). Reaction mixture
Figure imgf000016_0001
was diluted with water (20 mL), then NaHCC (5.4 mmol, 0.45 g) was added, and the reaction mixture was stirred additional 15 min. Ethyl acetate (50 mL) was added and layers were separated. Organic layer was washed with water (2 x 50 mL) and dried over Na2S04. Drying agent was filtered off and solvent was evaporated to dryness, and product was purified by column chromatography using hexanes/ethyl acetate gradient for elution fractions contained product were pooled together and evaporated to dryness to give 1.18 g of 6-O- acetyl -4-0-benzyl-3-0-trideuteroacetyl-2-deoxy-D-glucose (Yield 64.1%)
3.6. Synthesis of 6-0-acetyl-3-0-trideuteroacetyl-2-deoxy-D-glucose (23)
6-0-acetyl-4-0-benzyl-3-0-trideuteroacetyl-2-deoxy-D-glucose (1.18 g, 3.5 mmol) was dissolved in THL (18 mL). Pd(OH)2/C (20% wet, Degussa) (160 mg) was added and the mixture was hydrogenated using Paar apparatus (p = 45 psi) for 1 h, then reaction mixture was filtered trough Celite. filtrate was evaporated to dryness, and product was purified by column chromatography using DCM/Methanol gradient for elution fractions contained product were pooled together and evaporated to dryness to give 0.85 g of 6-0-acetyl-3-0- trideuteroacetyl-2-deoxy-D-glucose (Yield 97 %) (L25-98-2)
¾-NMR (DMSO-d6, d, ppm), 6.47 (d, 1H, J = 4.0 Hz), 5.33 (d, 1H, J = 6.1 Hz), 5.14 (dd,
1H, J = J = 3.0 Hz), 5.0 (ddd, 1H, J = 11.5 Hz, J = 9.2 Hz, J = 5.0 Hz), 4.25 (dd, 1H, J = 11.8 Hz, J = 1.8 Hz), 4.06 (dd, 1H, J = 11.7 Hz, J = 5.9 Hz), 3.86 (ddd, 1H, J = 7.6 Hz, J = 5.8 Hz, J = 1.8 Hz), 3.32 - 3.31 (m, 1H), 2.03 (s, 3H), 1.91 (dd, 1H, J = 12.3 Hz, J = 5.1 Hz), 1.55 - 1.44 (m, 1H); a isomer only
4. Synthesis of 3-0-acetyl-6-0-trideuteroacetyl-2-deoxy-D-glucose (28)
Figure imgf000017_0001
4.1. Synthesis of 4-0-benzyl-6-tert-butyldimethylsilyl-3-0-acetyl-D-glucal (24) 4-0-benzyl-6-tert-butyldimethylsilyl-3-0-acetyl-D-glucal (2.3 g, 6.8 mmol), was dissolved in dichloromethane (23 mL). Pyridine (1 mL) followed by acetyl anhydride (0.8 mL, 8.2 mmol) were added and the reaction mixture was stirred at room temperature. After reaction was completed (TLC) the reaction mixture was diluted with DCM (50 mL) and washed with 10% NaiCCh water solution, then with water until neutral and dried over NaiSCri. Drying agent was filtered off and solvent was evaporated to dryness, and product was purified by column chromatography using hexanes/ethyl acetate gradient for elution. Fractions contained product were pooled together and evaporated to dryness to give 2.25g of 4-0-benzyl-6-tert- butyldimethylsilyl-3-O-acetyl-D-glucal (Yield 83.8%). The structure of the product was confirmed by Ή NMR method and compared with literature.
4.2. Synthesis of 3-0-acetyl-4-0-benzyl-D-glucal (25)
4-0-benzyl-6-tert-butyldimethylsilyl-3 -O-acetyl -D-glucal (2.25 g, 5.7 mmol) was dissolved in THF (20 mL). Tetra-butylammonium fluoride (1.5 g, 5.7 mmol) was added and the reaction mixture was stirred at room temperature. After reaction was completed (TLC) solvent was
Figure imgf000018_0001
evaporated to dryness and ethyl acetate (50 mL) was added. Obtained solution was washed with water (3 x 50 mL) then dried over Na2S04. Drying agent was fdtered off and solvent was evaporated to dryness product was purified by column chromatography using hexanes/ethyl acetate gradient for elution. Fractions contained product were pooled together and evaporated to dryness to give 1.2 g of 3 -O-acetyl -4-0- benzyl-D-glucal (Yield 75.6%). The structure of the product was confirmed by Ή NMR method and compared with literature.
4.3. Synthesis of 3-0-acetyl-4-0-benzyl-6-0-trideuteroacetyl-D-glucal (26)
3-0-acetyl-4-0-benzyl-D-glucal (1.2 g, 4.3 mmol) was dissolved in dichloromethane (12 mL). Pyridine (0.76 mL) followed by per-deuterated acetyl anhydride (0.445 mL, 4.7 mmol) were added and the reaction mixture was stirred at room temperature overnight. After reaction was completed the reaction mixture was diluted with DCM (30 mL) and washed with 10% Na2C03 water solution, then with water until neutral and dried over NarSOu Drying agent was filtered off and solvent was evaporated to dryness, and product was purified by column chromatography using hexanes/ethyl acetate gradient for elution. Fractions contained product were pooled together and evaporated to dryness to give 1.31 g of 3 -O-acetyl -4-0-benzyl-6-0- trideuteroacetyl-D-glucal (yield 94.2%)
4.4. Synthesis of 3-0-acetyl-4-0-benzyl-6-0-trideuteroacetyl-2-deoxy-D-glucose (27)
3-0-acetyl-4-0-benzyl-6-0-trideuteroacetyl-D-glucal (1.3 g, 4.05 mmol) was dissolved in THF (13 mL). 48% HBr water solution (0.46 mL, 4.05 mmol) was added and the reaction mixture was stirred at room temp until all substrate was consumed (TLC). Reaction mixture was diluted with water (20 mL), then NaHC03 (4.05 mmol, 0.34 g) was added, and the reaction mixture was stirred additional 15 min. Ethyl acetate (30 mL) was added and layers were separated. Organic layer was washed with water (2 x 20 mL) and dried over NarSOu Drying agent was filtered off and solvent was evaporated to dryness, and product was purified by column chromatography using hexanes/ethyl acetate gradient for elution. Fractions
Figure imgf000019_0001
contained product were pooled together and evaporated to dryness to give 0.82 g of 3-0- acetyl-4-0-benzyl-6-0-trideuteroacetyl-2-deoxy-D-glucose (Yield 59.4 %)
4.5. Synthesis of 3-0-acetyl-6-0-trideuteroacetyl-2-deoxy-D-glucose (28)
3-0-acetyl-4-0-benzyl-6-0-trideuteroacetyl-2-deoxy-D-glucose (0.82 g, 2.4 mmol) was dissolved in THF (15 mL). Pd(OH)2/C (20% wet, Degussa) (150 mg) was added and the mixture was hydrogenated using Paar apparatus (p = 45 psi) for 1 h, then reaction mixture was filtered trough Celite. Filtrate was evaporated to dryness, and product was purified by column chromatography using DCM/Methanol gradient for elution Fractions contained product were pooled together and evaporated to dryness to give 0.57 g of 3-0-acetyl-6-0- trideuteroacetyl-2-deoxy-D-glucose (Yield 95 %) (F25-99-2)
¾-NMR (DMSO-d6, d, ppm), 6.47 (dd, 1H, J = 4.0 Hz, J = 1.4 Hz), 5.33 (d, 1H, J = 6.1 Hz), 5.17 dd, 1H, J = J = 3.1 Hz), 5.03 (ddd, 1H, J = 11.2 Hz, J = 9.3 Hz, J = 5.lHz), 4.25 (dd, 1H, J = 11.7 Hz, J = 1.8 Hz), 4.09 (dd, 1H, J = 11.7 Hz, J = 5.8 Hz), 3.89 (ddd, 1H, J = 9.7 Hz, J = 5.8 Hz, J = 1.8 Hz), 3.30 (ddd, 1H, J = 9.6 Hz, J = 9.5 Hz, J = 8.1 Hz), 2.02 (s, 3H), 1.94 (ddd, 1H, J = 12.5 Hz, J = 5.1 Hz, J = 1.1 Hz), 1.56 - 1.44 (m, 1H)
The particular combinations of elements and features in the above detailed embodiments are exemplary only; the interchanging and substitution of these teachings with other teachings in this and the patents/applications incorporated by reference are also expressly contemplated.
As those skilled in the art will recognize, variations, modifications, and other implementations of what is described herein can occur to those of ordinary skill in the art without departing from the spirit and the scope of the invention as claimed. Accordingly, the foregoing description is by way of example only and is not intended as limiting. In the claims, the word "comprising" does not exclude other elements or steps, and the indefinite article "a" or "an" does not exclude a plurality. The mere fact that certain measures are recited in mutually different dependent claims does not indicate that a combination of these measured cannot be used to advantage. The invention's scope is defined in the following claims and the
Figure imgf000020_0001
equivalents thereto. Furthermore, reference signs used in the description and claims do not limit the scope of the invention as claimed.

Claims

C l a i m s
1. Compounds according to structure (I)
Figure imgf000021_0002
whereby one of R1 to R3 is -OCOCD3 and the other two are either hydroxyl or OAc.
2. Compunds according to claim 1, whereby at least one of R1 to R3 is hydroxyl
3. Compounds according to claim 1 or 2, whereby either R1 or R3 is -OCOCD3.
4. A synthesis method for the compounds according to any of the claims 1 to 3, involving the steps of: a) reacting a suitable precursor compound with a silylating agent to obtain a monosilyl-protected precursor compound b) optinal protecting of further hydroxy groups of the compound obtained in step a) by orthogonal protective groups c) detachment of the silyl protective group
Figure imgf000022_0001
d) acetylation of the deprotected group to introduce a -CO-CD3 group e) optional deprotection of the protected hydroxy groups in step b)
5. The method of claim 4, whereby a sterically demanding silyl group is used in step a)
6. The method of claim 4 or 5, whereby a silyl group comprising aryl or t-butyl moieties is used in step a)
7. The method of any of the claims 4 to 6, whereby the silyl group in step a) is TBDMS (t-Butyldimetylsilyl) .
8. The method of any of the claims 4 to 7, whereby in step b) benzyl and/or substituted benzyl groups are used.
9. The method of any of the claims 4 to 8, thereby in step c) TBAF (Tertbutylammonium fluoride) is used
10. The method of any of the claims 4 to 9, whereby in step d) per-deuterated acetyl anhydride and/or deuterated acyl halides are used.
11. The method of any of the claims 4 to 10, whereby the precursor compound in step a) is a glucal or glucal derivative and the method includes a step f) which can be performed after step d) or e).
12. The method according to claim 11, whereby step f) is performed by first adding
aqueos solution of H-Hal (with Cl and Br especially preferred), followed by neutralization.
Figure imgf000023_0001
13. The method according to claim 12, whereby neutralization is performed using
carbonate, hydrogen carbonate and/or phosphate solution.
14. Use of a compound according to any of the claims 1 to 3 for compounds for the analysis of the metabolism of glycolysis inhibitors.
15. An analysis method method for the metabolism of glycolysis inhibitors including the step of subjecting a compound according to any of the claims 1 to 3 in an assay.
16. The method according to claim 15, whereby the assay is in vivo.
17. The method according to claim 16, whereby the assay is in vitro.
PCT/IB2019/056853 2018-08-13 2019-08-13 Molecular probes for analysis of metabolism of glycolysis inhibitors prodrugs and synthesis methods therefore WO2020035782A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18461599 2018-08-13
EP18461599.5 2018-08-13

Publications (1)

Publication Number Publication Date
WO2020035782A1 true WO2020035782A1 (en) 2020-02-20

Family

ID=63254659

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2019/056853 WO2020035782A1 (en) 2018-08-13 2019-08-13 Molecular probes for analysis of metabolism of glycolysis inhibitors prodrugs and synthesis methods therefore

Country Status (1)

Country Link
WO (1) WO2020035782A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010005799A2 (en) * 2008-07-11 2010-01-14 Board Of Regents, The University Of Texas System Novel acetates of 2-deoxy monosaccharides with anticancer activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010005799A2 (en) * 2008-07-11 2010-01-14 Board Of Regents, The University Of Texas System Novel acetates of 2-deoxy monosaccharides with anticancer activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FOKT IZABELA ET AL: "d-Glucose and d-mannose-based metabolic probes. Part 3: Synthesis of specifically deuterated d-glucose, d-mannose, and 2-deoxy-d-glucose", CARBOHYDRATE RESEARCH, PERGAMON, GB, vol. 368, 13 December 2012 (2012-12-13), pages 111 - 119, XP028970633, ISSN: 0008-6215, DOI: 10.1016/J.CARRES.2012.11.021 *
FOSTER A B: "Deuterium isotope effects in the metabolism of drugs and xenobiotics: implications for drug design", ADVANCES IN DRUG RESEARCH, ACADEMIC PRESS, LONDON, GB, vol. 14, 1 January 1985 (1985-01-01), pages 1 - 40, XP009086953, ISSN: 0065-2490 *

Similar Documents

Publication Publication Date Title
FI90429C (en) A process for the preparation of new therapeutically useful adenosine derivatives and intermediates
CN110785425B (en) Synthesis of 3 '-deoxyadenosine-5' -O- [ phenyl (benzyloxy-L-alanyl) ] phosphate (NUC-7738)
WO2019208571A1 (en) Amidite compound and method for producing polynucleotide using said compound
WO2017045582A1 (en) Preparation method of nucleoside phosphoramidate prodrugs and intermediates thereof
KR20180101370A (en) Selective Synthesis of Diastereomers of Phosphate Derivatives and Gemcitabine Prodrug NUC-1031
JP6084967B2 (en) Method for producing sepiapterin and tetrahydrolactoylpterin
EP3684780B1 (en) Floxuridine synthesis
CA2168080C (en) Process for the preparation of 1-(2'-deoxy-2',2'-difluoro- d-ribopentofuranosyl)-cytosine from 2-deoxy-2,2-difluoro- beta-d-ribo-pentopyranose
CN109641931B (en) Method for synthesizing ribonucleic acid H-phosphate monomer and oligonucleotide synthesis using the same
WO2020035782A1 (en) Molecular probes for analysis of metabolism of glycolysis inhibitors prodrugs and synthesis methods therefore
JPH051092A (en) Nucleoside derivative and its production
EP3838894A1 (en) Method for producing intermediate useful for synethesis of sglt inhibitor
EP2588482B1 (en) Preparation of tesetaxel and related compounds and corresponding synthesis intermediate
JPH11349541A (en) New intermediate for allosamizoline derivative
SU1630614A3 (en) Process for preparation natilmycin
EP4049996A1 (en) Glycoside compound, amidite compound, and production method for polynucleotide using said compounds
CN106279171A (en) A kind of preparation method of Idelalisib
KR20070063421A (en) A manufacturing process of 2',2'-difluoronucloside and intermediate
CN108314689A (en) 4,11- diacyl bergenin derivative synthetic methods
EP3016964A1 (en) Method for incorporating protecting acetal and acetal ester groups, and its application for the protection of hydroxyl function
JP2002293792A (en) Method for producing nucleoside or fluorinated sugar derivative
US9260401B2 (en) Method for preparing cabazitaxel from 10-deacetylbaccatin III in high yield, and novel intermediate therefor
JP2504934B2 (en) 1,6,7-Triacylforskolin derivative
CN117142996A (en) Monoamine inhibitor intermediate and synthetic method and application thereof
JP2023179354A (en) Method for producing morpholino nucleic acid using h-phosphonate technique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19773924

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19773924

Country of ref document: EP

Kind code of ref document: A1